Skip to main content
. 2017 Aug 12;3(1):73–80. doi: 10.1016/j.ekir.2017.08.003

Figure 1.

Figure 1

Change from baseline in (a) daily urinary phosphate excretion; and (b) daily fecal phosphorous excretion in study 1 (multiple ascending dose; study drug dosed 3 times daily for 7 days) in healthy subjects with 3 dose levels of ASP3325 and placebo. No apparent time- or dose-dependent changes in these pharmacodynamic assessments were observed. Data are expressed as mean ± SD.